Please review the following CME information before selecting the Begin the Program button found at the bottom of this page.
PROGRAM DESCRIPTION
The introduction of noninvasive procedures for facial rejuvenation is a relatively recent development in the subspecialty of cosmetic dermatology. As novel procedures and drugs continue to emerge, as the size of the population of Americans over 65 continues to expand, and as public awareness of the availability of these methods continues to grow, demand for facial rejuvenation treatment—already high—will increase. Clinicians who have an interest in aesthetic medicine have an opportunity to help patients who hope to improve their quality of life by reversing some of the effects of both intrinsic and extrinsic causes of facial aging. The products and procedures now available offer safe and effective treatments that yield satisfying results for both patients and clinicians.
This webcast, featuring expert presentations and live patient treatment is a comprehensive review of injectable dermal fillers and volumizers, products that comprise the arena of treatment known as nonsurgical total facial rejuvenation. This program, presented in a workshop format by leading authorities in dermatology, will review the science of skin aging, cover the advantages and drawbacks of each product currently used in facial rejuvenation, discuss expectations and realistic outcomes, and show, in live patient demonstrations, techniques for identifying treatment zones and injecting various products.
Intended Audience
This activity has been developed for dermatologists, plastic surgeons, and fellows and residents in plastic surgery and dermatology.
EDUCATIONAL OBJECTIVES
On completion of this activity, participants should be able to:
- Define the term “nonsurgical total facial rejuvenation” and list the currently available products that constitute the treatment options in this area.
- Explain the processes of both extrinsic and intrinsic facial aging, and discuss how nonsurgical total facial rejuvenation works to counter the effects of these aging processes.
- List and describe the advantages and limitations of each of the products currently used in nonsurgical total facial rejuvenation.
- Assess the treatment zones in individual patients for which various types of injectable fillers and volumizers would be appropriate and determine which treatment options are advisable for each case.
- Communicate effectively to patients the benefits and risks of the various available treatment options, determine their expectations, and educate them about realistic outcomes of therapy.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Skin Disease Education Foundation (SDEF). The EOCME is accredited by the ACCME to provide continuing medical education for physicians.
CME Credit Statement
The EOCME designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
FACULTY DISCLOSURES
As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty of this educational activity discloses the following.
Dr Mest has stock interests in Medicis and is a consultant for Bioform. He is also a consultant for and has received clinical funding for research from Dermik. He discusses unlabeled/investigational uses. Dr Werschler has stock interests in Allergan, Bioform, and Myoscience. He is a consultant, advisory board member, investigator, and/or speaker for Allergan, Amgen, Bioform, Clarisonic, Dermik, Galderma, Genentech, Medicis, Myoscience, and Peplin. He discusses unlabeled/investigational uses.
RESOLUTION OF CONFLICT OF INTEREST
The EOCME has implemented a process to resolve conflict of interest for each CME activity. In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, the EOCME has resolved the conflict by external content review.
UNAPPROVED/OFF-LABEL USE DISCLOSURE
The EOCME requires CME faculty to disclose to the participants:
- When products or procedures being discussed are off-label, unlabeled, experimental, and or investigational (not US Food and Drug Administration [FDA] approved); and
- Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research; interim analyses; and/or unsupported opinion.
Faculty may discuss information about pharmaceutical agents that are outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
This CME activity is supported by an educational grant from 
.
Special Needs
We encourage participation by all individuals. If you have any special needs, please contact mededinfo@elsevier.com for assistance.
Hardware and Software Specifications Needed to View
This course requires use of a modern web browser such as Microsoft Internet Explorer, Mozilla Firefox, Apple Safari, Netscape, or Opera. Additionally, to view the presentations requires Flash reader version 6 or later (free download here) and Acrobat Reader Version 5 or later (free download here).